In the present study, evaluating the percentage of MDSCs cells in CML patients defined as CD11b+CD33+CD14-HLADR- (Gr-MDSCs) and CD14+HLADR- (Mo-MDSCs), we found that both were significantly higher at diagnosis compared to HD and decreased to normal levels after IM therapy. The gene discussed is CD14; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.